DK2201963T3 - Glutamat-modulationsmidler i behandlingen af mentale lidelser - Google Patents

Glutamat-modulationsmidler i behandlingen af mentale lidelser Download PDF

Info

Publication number
DK2201963T3
DK2201963T3 DK10156331.0T DK10156331T DK2201963T3 DK 2201963 T3 DK2201963 T3 DK 2201963T3 DK 10156331 T DK10156331 T DK 10156331T DK 2201963 T3 DK2201963 T3 DK 2201963T3
Authority
DK
Denmark
Prior art keywords
glutamate
disorder
treatment
reuptake inhibitor
ocd
Prior art date
Application number
DK10156331.0T
Other languages
English (en)
Inventor
Vladmir Coric
John H Krystal
Gerard Sanacora
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of DK2201963T3 publication Critical patent/DK2201963T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/10—Optical coatings produced by application to, or surface treatment of, optical elements
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/20—Filters
    • G02B5/28—Interference filters
    • G02B5/281—Interference filters designed for the infrared light
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/20—Filters
    • G02B5/28—Interference filters
    • G02B5/283—Interference filters designed for the ultraviolet
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/20—Filters
    • G02B5/28—Interference filters
    • G02B5/285—Interference filters comprising deposited thin solid films
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F39/00—Integrated devices, or assemblies of multiple devices, comprising at least one element covered by group H10F30/00, e.g. radiation detectors comprising photodiode arrays
    • H10F39/011—Manufacture or treatment of image sensors covered by group H10F39/12
    • H10F39/024—Manufacture or treatment of image sensors covered by group H10F39/12 of coatings or optical elements
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F39/00—Integrated devices, or assemblies of multiple devices, comprising at least one element covered by group H10F30/00, e.g. radiation detectors comprising photodiode arrays
    • H10F39/80—Constructional details of image sensors
    • H10F39/805—Coatings
    • H10F39/8053—Colour filters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

1. Anvendelse af N-acetylcystein eller farmaceutisk acceptabelt salt deraf i fremstillingen af et medikament til behandlingen af en mental lidelse.
2. Anvendelsen ifølge krav 1, hvor N-acetylcysteinet svækker præsynaptisk glutamatfrigivelse eller normaliserer, forøger, eller potentierer optagelsen af glutamat over glia-cellerne.
3. Anvendelsen ifølge krav 1, hvor den mentale lidelse er større depressionslidelser.
4. Anvendelsen ifølge krav 3, hvor den mentale lidelse er bipolar lidelse.
5. Anvendelse ifølge krav 1 eller 2, hvor den mentale lidelse er en angstlidelse.
6. Anvendelsen ifølge krav 5, hvor angstlidelsen er tvangshandling.
7. Anvendelsen ifølge krav 6, hvor tvangshandlingen er en serotonin-genoptagelses-hæmmer-refraktorisk tvangshandling.
8. Anvendelsen ifølge kravene 1-3, hvor den mentale lidelse er en impuls-kontrollidelse.
9. Anvendelsen ifølge krav 8, hvor impuls-kontrollidelsen er trichotillomani.
10. Anvendelsen ifølge krav 1, hvor den mentale lidelse er en kognitiv forstyrrelse.
11. Anvendelsen ifølge krav 10, hvor den kognitive forstyrrelse er demens.
12. Anvendelsen ifølge krav 1, hvor den mentale forstyrrelse er skizofreni.
13. Anvendelse ifølge krav 1, yderligere omfattende anvendelse afen serotonin-genoptagelses-hæmmer i fremstillingen af et medikament.
14. Anvendelsen ifølge krav 13, hvor serotonin-genoptagelses-hæmmeren er citalopram, escitalopram, flouxetin, fluvoxamin, paroxetin, sertralin, trazodon, venlafaxin, mirtazapin eller clomipramin.
15. Anvendelsen ifølge krav 13 eller 14, hvor N-acetylcysteinet eller salt deraf og SRI'en kombineres med andre psykotrofe medikamenter valgt fra et anti-psykotikum, et krampestillende middel, en tricyklisk antidepressiv, en monoaminoxidase-hæmmer, en selektiv serotonin-genoptagelses-hæmmer, en selektiv serotonin-norepinephrin-genoptagelses-hæmmer, en norepinephrindopamin-genoptagelses-hæmmer, en serotonin-2-antagonist-genoptagelses-hæmmer, en benzodiazepin, et middel til fremmelse af vågentilstand, et anti-manisk middel eller en kombination deraf.
16. Farmaceutisk sammensætning omfattende en serotonin-genoptagelses-hæmmer og N-acetylcystein eller et farmaceutisk acceptabelt salt deraf.
17. Farmaceutisk sammensætning ifølge krav 16, hvor serotonin-genoptagelses-hæmmeren er mindst én af følgende: citalopram, escitalopram, flouxetin, fluvoxamin, paroxetin, sertralin, trazodon, venlafaxin, mirtazepin, clomipramin, eller en kombination af serotonin-genoptagelses-hæmmeren med mindst et af andre psykotrofe medikamenter valgt fra gruppen bestående af et anti-psykotikum, et krampestillende middel, en tricyklisk antidepressiv, en monaminoxidase-hæmmer, en selektiv serotonin-genoptagelses-hæmmer, en selektiv serotoninnorepinephrin-genoptagelses-hæmmer, en norepinephrindopamin-genoptagelses-hæmmer, en serotonin-2 antagonist-genoptagelses-hæmmer, en benzodiazepin, et middel til fremmelse af vågentilstanden, et anti-manisk middel, eller en kombination af ét eller flere af de foregående.
DK10156331.0T 2005-04-05 2006-04-05 Glutamat-modulationsmidler i behandlingen af mentale lidelser DK2201963T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66873505P 2005-04-05 2005-04-05
US66977405P 2005-04-07 2005-04-07
US69018705P 2005-06-13 2005-06-13
US69462105P 2005-06-27 2005-06-27
US75647206P 2006-01-04 2006-01-04
EP06749354A EP1874353A1 (en) 2005-04-05 2006-04-05 Glutamate modulating agents in the treatment of mental disorders

Publications (1)

Publication Number Publication Date
DK2201963T3 true DK2201963T3 (da) 2016-02-15

Family

ID=36659964

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10156331.0T DK2201963T3 (da) 2005-04-05 2006-04-05 Glutamat-modulationsmidler i behandlingen af mentale lidelser

Country Status (11)

Country Link
US (7) US8778979B2 (da)
EP (4) EP2201963B1 (da)
CY (1) CY1124111T1 (da)
DK (1) DK2201963T3 (da)
ES (2) ES2819303T3 (da)
HU (1) HUE050758T2 (da)
LT (1) LT2982372T (da)
PL (1) PL2982372T3 (da)
PT (1) PT2982372T (da)
SI (1) SI2982372T1 (da)
WO (1) WO2006108055A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006209216A1 (en) 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
EP2201963B1 (en) 2005-04-05 2016-01-27 Yale University Glutamate modulating agents in the treatment of mental disorders
CA2667052A1 (en) * 2006-10-23 2008-05-02 The Mental Health Research Institute Of Victoria Combination therapy
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
EP2252596B1 (en) * 2008-02-07 2016-12-28 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
AU2010213683B2 (en) 2009-02-12 2016-04-21 Indiana University Research & Technology Corporation Material and methods for treating developmental disorders including comorbid and idiopathic autism
EP2614821B1 (en) * 2010-09-06 2016-11-09 SNU R & DB Foundation Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof
US20120270860A1 (en) * 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
US10639298B2 (en) 2015-03-03 2020-05-05 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
WO2016184911A1 (en) * 2015-05-18 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of the neuropathology of patients suffering from myotonic dystrophy type 1 (dm1)
KR20210045423A (ko) * 2018-08-16 2021-04-26 바이오하벤 테라퓨틱스 리미티드 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도
BR112022025901A2 (pt) * 2020-06-24 2023-01-10 Biohaven Therapeutics Ltd Composições e métodos para tratar transtorno obsessivo-compulsivo
EP4584250A4 (en) * 2022-09-06 2026-02-25 Biohaven Therapeutics Ltd POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5310897A (en) 1984-12-27 1994-05-10 Sumitomo Pharmaceuticals Co., Ltd. Beta-lactams and their production
ATE55245T1 (de) 1986-04-16 1990-08-15 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
JP3158435B2 (ja) 1989-10-26 2001-04-23 日本新薬株式会社 徐放性製剤
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5057321A (en) 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5104761A (en) 1990-09-14 1992-04-14 Eastman Kodak Company Interdispersed three-phase ferrite composite and electrographic magnetic carrier particles therefrom
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
AU721653B2 (en) 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
IL139672A (en) * 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia
US6031094A (en) 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US6387956B1 (en) * 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US6228888B1 (en) * 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
US6610681B1 (en) 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001041707A2 (en) * 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
JP2001328947A (ja) * 2000-05-19 2001-11-27 Ritsuko Senba 脳由来神経栄養因子発現促進剤
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US20030162694A1 (en) * 2002-02-04 2003-08-28 James Meyerhoff Novel treatment for pathological aggression
EP1595535A2 (en) 2002-12-23 2005-11-16 Osmotica Costa Rica Sociedad Anonima Delivery device containing venlafaxine and memantine and use method thereof
ATE433993T1 (de) * 2003-02-26 2009-07-15 Univ Johns Hopkins Modulatorische verbindungen und verfahren für glutamattransport
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8252331B2 (en) 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20060167068A1 (en) 2005-01-26 2006-07-27 Seth Feuerstein Method of treating self-injurious behavior with glutamate modulating agents
EP2201963B1 (en) 2005-04-05 2016-01-27 Yale University Glutamate modulating agents in the treatment of mental disorders
KR100748513B1 (ko) 2005-10-07 2007-08-14 엘지전자 주식회사 위치 서비스 방법 및 시스템
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires

Also Published As

Publication number Publication date
EP1874353A1 (en) 2008-01-09
US20180318288A1 (en) 2018-11-08
ES2564187T3 (es) 2016-03-18
EP2201963B1 (en) 2016-01-27
SI2982372T1 (sl) 2020-11-30
US10052318B2 (en) 2018-08-21
ES2819303T3 (es) 2021-04-15
US20210294011A1 (en) 2021-09-23
CY1124111T1 (el) 2022-03-24
EP2982372B1 (en) 2020-08-05
US20170360775A1 (en) 2017-12-21
US20210093629A1 (en) 2021-04-01
PT2982372T (pt) 2020-10-09
EP2982372A1 (en) 2016-02-10
US20210093630A1 (en) 2021-04-01
US11554117B2 (en) 2023-01-17
LT2982372T (lt) 2020-10-26
EP3753561A1 (en) 2020-12-23
EP2201963A1 (en) 2010-06-30
US20060270647A1 (en) 2006-11-30
HUE050758T2 (hu) 2021-01-28
US20140249173A1 (en) 2014-09-04
WO2006108055A1 (en) 2006-10-12
PL2982372T3 (pl) 2020-12-28
US8778979B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
US11554117B2 (en) Glutamate agents in the treatment of mental disorders
Johnson et al. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence
Findling et al. Quetiapine in nine youths with autistic disorder
Chez et al. Secretin and autism: a two-part clinical investigation
Wolterink et al. Relative roles of ventral striatal D1 and D2 dopamine receptors in responding with conditioned reinforcement
Arnold et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia
AU2018265353A1 (en) Methods of treating Doose syndrome using fenfluramine
US12138254B2 (en) Chronic nightly dosing of lasmiditan for migraine prevention
JP2024178168A (ja) ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
Kato et al. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT
Reghunandanan et al. Obsessive-compulsive and related disorders
Pilcher et al. Scopolamine Impairs Spatial Working Memory in the Radial Maze: An Analysis by Error Type and Arm Choice1
Goddard et al. A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder
Hall et al. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial
Saiz-Ruiz et al. Tianeptine therapy for depression in the elderly
Boshes et al. Review of antipsychotic medication administration: a proposal of intermittent dosing
Stein et al. Obsessive-compulsive disorder
Haddadi et al. Neuroprotective effects of methylphenidate on diffuse axonal injury in acute traumatic brain injury patients
KR20240161650A (ko) 조현병 환자에서 재발을 예방하는 데 있어서 롤루페리돈의 용도
KR20230027189A (ko) 강박 장애를 치료하기 위한 조성물 및 방법
Radin et al. Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD–A phase 2A clinical trial
Ralevski et al. Effects of naltrexone on cognition in a treatment study of patients with schizophrenia and comorbid alcohol dependence
Lynn et al. Use of multiple naloxone administrations in the emergency department: A retrospective claims-based analysis
Markowitz et al. A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder
Young baclofen and psych problems